Informed Momentum Co LLC Acquires Shares of 852,215 Senseonics Holdings, Inc. (NYSE:SENS)

Key Points

• Informed Momentum Co LLC acquired 852,215 shares of Senseonics Holdings, Inc., valued at approximately $559,000, making up 0.13% of the company's total shares.
• A number of analysts have set a consensus rating of "Buy" for Senseonics, with an average target price of $1.55, highlighting positive market sentiment.
• Senseonics specializes in continuous glucose monitoring systems for diabetes management, reflecting its focus on medical technology innovations.

Informed Momentum Co LLC bought a new position in Senseonics Holdings, Inc. (NYSE:SENS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 852,215 shares of the company's stock, valued at approximately $559,000. Informed Momentum Co LLC owned 0.13% of Senseonics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Millennium Management LLC boosted its holdings in Senseonics by 299.0% in the 4th quarter. Millennium Management LLC now owns 1,088,029 shares of the company's stock worth $569,000 after acquiring an additional 815,332 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Senseonics in the fourth quarter valued at $26,000. Renaissance Technologies LLC acquired a new stake in Senseonics during the 4th quarter valued at $720,000. Two Sigma Investments LP acquired a new position in Senseonics in the 4th quarter worth $36,000. Finally, Cambridge Investment Research Advisors Inc. boosted its position in Senseonics by 679.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 289,919 shares of the company's stock valued at $190,000 after buying an additional 252,745 shares during the last quarter. Hedge funds and other institutional investors own 12.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SENS shares. HC Wainwright reaffirmed a "buy" rating and set a $1.40 target price (up from $1.10) on shares of Senseonics in a research report on Tuesday, July 8th. TD Cowen initiated coverage on Senseonics in a report on Tuesday, July 15th. They set a "buy" rating and a $1.25 price objective on the stock. Wall Street Zen raised Senseonics to a "sell" rating in a research report on Monday, May 12th. Finally, Lake Street Capital upgraded Senseonics to a "strong-buy" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a sell rating, two have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $1.55.

Senseonics Stock Performance

Shares of Senseonics stock opened at $0.47 on Wednesday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics Holdings, Inc. has a 1 year low of $0.25 and a 1 year high of $1.40. The firm's 50-day simple moving average is $0.51 and its 200-day simple moving average is $0.66. The firm has a market cap of $309.71 million, a PE ratio of -3.64 and a beta of 0.88.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.